DARIOHEALTH CORP (DRIO)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$7.24+3.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
Broken: Primary pillar broken — Sustain revenue growth near 49% next year: FY27 rev est $31.5M vs FY26 $21.7M (+45.2%) vs 48% target.
DarioHealth is growing revenue from $5.23M to $5.58M in recent quarters. Analysts expect nearly 49% revenue growth next year. The company is expanding through partnerships and market growth. Its cheap valuation reflects the risk but offers upside if growth continues.
DarioHealth is loss-making with worsening EPS estimates. Revenue growth may slow as recent estimate revisions are down. The company faces volatile management and high risk. The stock has fallen 17% from its high, showing market doubts.
The price is about 58% below our fair value near $17. Analysts expect 49% revenue growth, but EPS losses are expected to continue. The market prices in a risky turnaround with growth potential but uncertain profitability.
Breaks if: New large equity or debt issuance announced
Breaks if: EPS loss worsens beyond -$0.70 per share next year
Breaks if: YoY revenue growth falls below 30% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown volatility in management and financial performance, which adds to the uncertainty of its growth trajectory.
The market appears to price in a low level of fragility, as indicated by a low expectations gap. Valuation is considered cheap compared to peers, suggesting that the market may not fully reflect the potential upside or downside risks.
Management is focused on raising capital and increasing revenue growth, but recent results show limited progress in these areas. With revenue declining and gross profit margins under pressure, the fundamentals may struggle to improve in the near term.
The future performance of DRIO hinges on broader sector trends, particularly the performance of key industry players. If these bellwethers continue to perform well, it could provide a favorable environment for DRIO, but any negative shifts could pose significant risks.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The earnings call highlighted strong revenue growth from the multi-condition platform. However, the company beat earnings expectations, but revenue fell short of estimates. This shortfall impacts the growth objective and raises concerns about future performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on growing revenue through commercial scaling and expanding partnerships in healthcare markets.
Newly stated in 2026-Q2 period. Management highlighted accelerating commercial scaling and partnerships as key to growth. However, revenue declined from $7.6 million in 2024-Q4 to $5.2 million in 2026-Q2, indicating limited progress on revenue growth despite stated strategic focus.
Over the next 1 to 3 years, DRIO's outlook remains uncertain, influenced by both internal management execution and external market conditions. Not investment advice.